How have ZLDAF shares performed in 2024?

Zelira Therapeutics' stock was trading at $0.5896 on January 1st, 2024. Since then, ZLDAF stock has decreased by 18.6% and is now trading at $0.48. View the best growth stocks for 2024 here .

When did Zelira Therapeutics' stock split?

Zelira Therapeutics's stock reverse split before market open on Monday, April 18th 2022. The 1-175 reverse split was announced on Monday, April 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Zelira Therapeutics?

Shares of ZLDAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:ZLDAF

Zelira Therapeutics (ZLDAF) Stock Price, News & Analysis

→ A new way to collect income from stocks (From DTI) (Ad)

Free ZLDAF Stock Alerts

$0.48

0.00 (0.00%)

(As of 04/24/2024 ET)

Compare

Today's Range: $0.48
▼
$0.48
50-Day Range: $0.47
▼
$0.60
52-Week Range: $0.47
▼
$1.65

Volume: N/A
Average Volume: 1,300 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Short Interest

Get Zelira Therapeutics alerts:

Ad Banyan Hill Publishing

The Best AI Stock to Own in the World Today is Trading for Just $25

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

See how you can invest alongside him

About Zelira Therapeutics Stock (OTCMKTS:ZLDAF)

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. The company offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. It also provides over the counter products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.

ZLDAF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ZLDAF Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive ZLDAF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zelira Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: OTCMKTS:ZLDAF
CUSIP: N/A
CIK: N/A
Web: www.zeldatherapeutics.com
Phone: (186) 558-0886
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Osagie O. Imasogie Esq. (Age 62)
Founder & Chairman
Comp: $93.24k
Dr. Oludare Odumosu
MD, Global CEO & Director
Mr. Greg Blake
Executive Director
Mr. Timothy Ryan Slate
Company Secretary & Non-Executive Director
Mr. Rahul Ganesan
Vice President of Finance & Accounting
Dr. Patty Washer
Clinical Trial Consultant

Key Competitors

View All Competitors

ZLDAF Stock Analysis - Frequently Asked Questions

How have ZLDAF shares performed in 2024?: Zelira Therapeutics' stock was trading at $0.5896 on January 1st, 2024. Since then, ZLDAF stock has decreased by 18.6% and is now trading at $0.48.
View the best growth stocks for 2024 here.
When did Zelira Therapeutics' stock split?: Zelira Therapeutics's stock reverse split before market open on Monday, April 18th 2022. The 1-175 reverse split was announced on Monday, April 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.
How do I buy shares of Zelira Therapeutics?: Shares of ZLDAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ZLDAF) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial